黄体生成素/绒毛膜促性腺激素受体（英語： luteinizing hormone/choriogonadotropin receptor ，缩写LHCGR也作 lutropin/choriogonadotropin receptor，LCGR或luteinizing hormone receptor，LHR ）是一种主要出现在卵巢和睾丸的跨膜受体，但在一些性腺外的器官如子宫和乳房也有表达。

2024年12月25日 · LHCGR (Luteinizing Hormone/Choriogonadotropin Receptor) is a Protein Coding gene. Diseases associated with LHCGR include Precocious Puberty, Male-Limited and Leydig Cell Hypoplasia, Type I. Among its related pathways are Class A/1 (Rhodopsin-like receptors) and GPCR downstream signalling.

The luteinizing hormone/choriogonadotropin receptor (LHCGR), also lutropin/choriogonadotropin receptor (LCGR) or luteinizing hormone receptor (LHR), is a transmembrane receptor found predominantly in the ovary and testis, but also many extragonadal organs such as …

The LHCGR is able to differentiate the activity of luteinizing hormone and chorionic gonadotropin. A novel point mutation of the LHCGR gene has been identified in a family affected with FMPP. The c.1703C>T mutant LHCGR was confirmed to be constitutively active, which has led to maturation and proliferation of Leydig cells.

2022年5月21日 · LHCGR expression predominates in ovarian tissues where it elicits functional responses through cyclic adenosine mononucleotide (cAMP), Ca 2+ and extracellular signal-regulated kinase (ERK)...

2021年12月7日 · 揭示出绒毛膜促性腺激素 （CG）识别LHCGR的分子机制及小分子化合物Org43553与受体LHCGR相互作用模式，鉴定了糖蛋白激素选择性结合LHCGR和促卵泡激素受体的关键氨基酸残基，提出了激素配体激活受体的“Push and Pull”模型。

The LHCGR gene provides instructions for making a receptor protein called the luteinizing hormone/chorionic gonadotropin receptor. Receptor proteins have specific sites into which certain other proteins, called ligands, fit like keys into locks.

该基因的突变导致男性第二性征发育障碍，包括家族性男性性早熟，也称为睾丸毒症、低促性腺激素性性腺功能减退症、间质细胞腺瘤伴性早熟和男性假两性畸形伴间质细胞发育不全。 [RefSeq 提供，2008 年 7 月] This gene encodes the receptor for both luteinizing hormone and choriogonadotropin. This receptor belongs to the G-protein coupled receptor 1 family, and its activity is mediated by G proteins which activate Adenylate Cyclase.

2025年1月7日 · 促黄体素（luteinizing hormone，LH）和绒毛膜促性腺激素（chorionic gonadotropin，CG）是糖蛋白激素（glycoprotein hormones，GPH），调控着下丘脑-垂体-性腺轴的关键生理功能，如人体的性别发育和第二性征的发育与维持等。 LH和CG是目前临床重要的治疗药物，它们通过促黄体生成素-绒毛膜促性腺激素受体（LHCGR）的胞外结构域结合来激活激活下游信号通路，调控下游激素的合成与分泌，如LH用于辅助生殖、CG用于诱导女性排卵等。 尽 …

黄体生成素/ 绒毛膜促性腺激素 受体 (LHCGR)在LC分化和睾酮合成中起重要作用。 Lhcgr 突变导致睾酮缺乏，进而导致性发育受损、精子发生受阻和不育，是HPH的原型。 睾酮替代疗法 (TRT)是治疗HPH的首选，因为外源性TRT可以在很大程度上逆转低 血清睾酮 水平，并部分改善性腺功能减退相关症状。 然而，外源性TRT会引起许多不良反应，如睡眠呼吸暂停、中风、心脏病发作和前列腺肿瘤发生。 因此，迫切需要开发更安全的HPH治疗方法。 干间质细胞 (SLC)能够通过增 …